Clinical Trial

A Study of IOV-5001 in Adults With Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Trial Details
NCT Number NCT07743723
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Enrollment 106 participants
Start Date 2026-08
Primary Completion 2034-03 (estimated)
Study Completion 2044-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-06